{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-295465","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2021-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.205410+00:00","generated_at":"2026-06-28T21:46:28.222916+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Vanda's Corporate Affairs & Communications Officer Aranthan Jones II resigns, effective Oct 26, 2021","bullets":["Aranthan 'AJ' Jones II resigns as Corporate Affairs and Communications Officer, effective October 26, 2021.","Jones is leaving to join a U.S.-based publicly traded company outside the biopharmaceutical sector.","No successor has been announced at this time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-295465","json":"https://secwatch.observer/filing/0001193125-21-295465.json","markdown":"https://secwatch.observer/filing/0001193125-21-295465.md","text":"https://secwatch.observer/filing/0001193125-21-295465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000119312521295465/0001193125-21-295465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000119312521295465/d238861d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T21:46:28.222916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"96dc1ec3ef","claim":"Aranthan Jones II resigned as Corporate Affairs and Communications Officer at Vanda Pharmaceuticals Inc..","evidence_excerpt":"On October 6, 2021, Aranthan “AJ” Jones II notified Vanda Pharmaceuticals Inc. of his resignation as the Company’s Corporate Affairs and Communications Officer, effective as of October 26, 2021, in order to join a U.S.-based, publicly traded company outside of the biopharmaceutical sector.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312521295465/0001193125-21-295465-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Corporate Affairs and Communications Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}